ClicBio
Private Company
Funding information not available
Overview
ClicBio is a preclinical-stage biotech founded in 2021, pioneering a new class of oral, small-molecule CLIC1 inhibitors for obesity and metabolic disease. The company's science is based on inhibiting CLIC1, a protein that translocates to the membrane of hunger-promoting AgRP neurons during fasting; blocking this process reduces food intake, increases energy expenditure, and may offer a superior side-effect profile compared to GLP-1 therapies. With a seasoned leadership team of biotech veterans and a clear path toward clinical development, ClicBio is positioning itself to compete in the massive obesity market, either as a monotherapy or in combination with existing treatments. The company is privately held and headquartered in Cambridge, Massachusetts.
Technology Platform
Small-molecule inhibitors targeting the CLIC1 protein, a dimorphic chloride channel that translocates to the membrane of hypothalamic AgRP neurons to promote hunger. Inhibition blocks this translocation, reducing neuronal activity and appetite.
Opportunities
Risk Factors
Competitive Landscape
ClicBio competes in the crowded obesity therapeutics market, dominated by GLP-1 agonists (e.g., semaglutide, tirzepatide) from Novo Nordisk and Eli Lilly. Its differentiation lies in its novel central nervous system target (CLIC1), oral small-molecule format, and potential for improved GI tolerability. Competitors include other companies pursuing non-GLP-1 central mechanisms (e.g., amylin analogs, leptin sensitizers) and next-generation oral GLP-1 agonists.